Business & Consumer Services » Consumer Services | Blake Insomnia Therapeutics Inc.

Blake Insomnia Therapeutics Inc. | Income Statement

Fiscal year is September-August. All values USD Thousands.
2013
2014
2015
2016
2017
2018
SG&A Expense
8.80
219.60
36.00
32.70
95.80
28.30
EBIT
8.80
219.60
36.00
32.70
98.40
31
Interest Expense
-
-
-
5.00
11.90
14
Pretax Income
8.80
219.60
36.00
37.70
110.30
45
Consolidated Net Income
8.80
219.60
36.00
37.70
110.30
45
Net Income
8.80
219.60
36.00
37.70
110.30
45
Net Income After Extraordinaries
8.80
219.60
36.00
37.70
110.30
45
Net Income Available to Common
8.80
219.60
36.00
37.70
110.30
45
EPS (Basic)
0.00
0.01
0.00
0.00
0.00
1.38
Basic Shares Outstanding
10,597.60
23,485.20
31,490.70
31,597.60
31,597.60
32.50
EPS (Diluted)
0.00
0.01
0.00
0.00
0.00
1.38
Diluted Shares Outstanding
10,597.60
23,485.20
31,490.70
31,597.60
31,597.60
32.50
EBITDA
8.80
219.60
36.00
32.70
98.40
31
Other Operating Expense
-
-
-
-
2.60
2.70

About Blake Insomnia Therapeutics

View Profile
Address
244 5th Avenue
New York New York 10001
United States
Employees -
Website http://www.blakeinsomnia.com
Updated 07/08/2019
Blake Insomnia Therapeutics, Inc. operates as a pharmaceutical company, which provides insomnia remedy. The firm has developed Zleepax, which is a sleep aid with beta blockers as the major active agent. The company was founded by Briger Jan Olsen on August 11, 2012 and is headquartered in New York, NY.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.